SEC Company Response from AIM ImmunoTech Inc. (AIM) (CIK 0000946644) (AIM) — Oct 10, 2017

AIM ImmunoTech Inc. (AIM) (CIK 0000946644)
Date: Oct. 10, 2017 · CIK: 0000946644 · Accession: 0001493152-17-011448

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-220756

Date

October 12, 2017

Author

Director

Form

CORRESP

Company

AIM ImmunoTech Inc. (AIM) (CIK 0000946644)

Letter

Division of Corporation Finance Securities and Exchange Commission (SEC filing No. 333-220756) Acceleration Request Requested Date: October 12, 2017 Requested Time: 4:00 P.M. Eastern Time

Dear Ms. Hayes:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Hemispherx Biopharma, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-220756) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Silverman Shin & Byrne PLLC, by calling Richard Feiner, Esq. at (646) 822-1170.

Very
truly yours,
HEMISPHERX
BIOPHARMA, INC.

Show Raw Text

CORRESP
1
filename1.htm

HEMISPHERX
BIOPHARMA, INC.

1617
JFK Boulevard

Philadelphia,
Pennsylvania 19103

October
10, 2017

Suzanne
Hayes, Esq.

Assistant
Director

Division
of Corporation Finance

Securities
and Exchange Commission

100
F Street, NE

Washington,
DC 20002

    Re:
    Hemispherx Biopharma, Inc.

    Registration Statement on Form S-1

    (SEC filing No. 333-220756)

    Acceleration Request

    Requested Date:   October 12, 2017

    Requested Time:  4:00 P.M. Eastern Time

Dear
Ms. Hayes:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Hemispherx Biopharma, Inc. (the “Company”) hereby requests
that the above-referenced Registration Statement on Form S-1 (File No. 333-220756) (the “Registration Statement”)
be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time
as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the
Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event
with our counsel, Silverman Shin & Byrne PLLC, by calling Richard Feiner, Esq. at (646) 822-1170.

    Very
    truly yours,

    HEMISPHERX
    BIOPHARMA, INC.

    By:
    /s/
    Adam     Pascale

    Adam
    Pascale,

    Chief
    Financial Officer

    cc:
    Richard Feiner, Esq.

SecProbe.io